Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...
Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than ...
Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...
The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback